Kennedy has already insinuated that the use of GLP-1s in children could raise the specter of unforeseen problems that interrupt, damage, or impair metabolism and growth development, in his controversial MAHA Report
What are the main side effects, and who is a good candidate for this program
Ro's current public cash pricing centers on branded products and does not support publishing that old compounded price as a current option
If oral amycretin performs well, Novo could compete not only in injectable obesity care but also in the next major access-expansion segment
If tolerated, the documented approach is to stay at the current step for the full interval before the next scheduled escalation not to leapfrog steps
Working with a dietitian or nutritionist can also be extremely helpful in understanding why a GLP-1 may not be working